The cost of time: Haphazard discounting and the undervaluation of regulatory benefits

Research output: Contribution to journalArticle

Abstract

When performing cost-benefit analyses, regulators typically use willingness-to-pay studies to determine how much to spend to avert risks. Because money has a time-value, when a risk is valued is inextricable from how much it is valued. Unfortunately, the studies on which regulators rely are insensitive to this fact: they elicit people's willingness to pay for risk reductions without identifying the time at which the risk reduction will occur. Relying on these time-indeterminate studies has led to a systematic skew in regulatory cost-benefit analysis, toward the undervaluation of risks to human lives. Insofar as cost-benefit analyses inform regulation, this suggests that the current system systematically under regulates against risks to health and safety.

Original languageEnglish (US)
Pages (from-to)1505-1542
Number of pages38
JournalNotre Dame Law Review
Volume85
Issue number4
StatePublished - Jun 1 2010
Externally publishedYes

Fingerprint

costs
willingness to pay
cost-benefit analysis
time
money
regulation
health
Values

ASJC Scopus subject areas

  • Law

Cite this

The cost of time : Haphazard discounting and the undervaluation of regulatory benefits. / Rowell, Arden.

In: Notre Dame Law Review, Vol. 85, No. 4, 01.06.2010, p. 1505-1542.

Research output: Contribution to journalArticle

@article{a6615656a5ad432bb5d1bcff3c18c081,
title = "The cost of time: Haphazard discounting and the undervaluation of regulatory benefits",
abstract = "When performing cost-benefit analyses, regulators typically use willingness-to-pay studies to determine how much to spend to avert risks. Because money has a time-value, when a risk is valued is inextricable from how much it is valued. Unfortunately, the studies on which regulators rely are insensitive to this fact: they elicit people's willingness to pay for risk reductions without identifying the time at which the risk reduction will occur. Relying on these time-indeterminate studies has led to a systematic skew in regulatory cost-benefit analysis, toward the undervaluation of risks to human lives. Insofar as cost-benefit analyses inform regulation, this suggests that the current system systematically under regulates against risks to health and safety.",
author = "Arden Rowell",
year = "2010",
month = "6",
day = "1",
language = "English (US)",
volume = "85",
pages = "1505--1542",
journal = "Notre Dame Law Review",
issn = "0745-3515",
publisher = "Notre Dame Law School",
number = "4",

}

TY - JOUR

T1 - The cost of time

T2 - Haphazard discounting and the undervaluation of regulatory benefits

AU - Rowell, Arden

PY - 2010/6/1

Y1 - 2010/6/1

N2 - When performing cost-benefit analyses, regulators typically use willingness-to-pay studies to determine how much to spend to avert risks. Because money has a time-value, when a risk is valued is inextricable from how much it is valued. Unfortunately, the studies on which regulators rely are insensitive to this fact: they elicit people's willingness to pay for risk reductions without identifying the time at which the risk reduction will occur. Relying on these time-indeterminate studies has led to a systematic skew in regulatory cost-benefit analysis, toward the undervaluation of risks to human lives. Insofar as cost-benefit analyses inform regulation, this suggests that the current system systematically under regulates against risks to health and safety.

AB - When performing cost-benefit analyses, regulators typically use willingness-to-pay studies to determine how much to spend to avert risks. Because money has a time-value, when a risk is valued is inextricable from how much it is valued. Unfortunately, the studies on which regulators rely are insensitive to this fact: they elicit people's willingness to pay for risk reductions without identifying the time at which the risk reduction will occur. Relying on these time-indeterminate studies has led to a systematic skew in regulatory cost-benefit analysis, toward the undervaluation of risks to human lives. Insofar as cost-benefit analyses inform regulation, this suggests that the current system systematically under regulates against risks to health and safety.

UR - http://www.scopus.com/inward/record.url?scp=77956366645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956366645&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77956366645

VL - 85

SP - 1505

EP - 1542

JO - Notre Dame Law Review

JF - Notre Dame Law Review

SN - 0745-3515

IS - 4

ER -